In case you missed it: July 5 to July 9
It was a very busy week for the Contemporary OB/GYN® team.
This week’s top articles included:
Surprise bills for childbirth
In addition to welcoming a newborn, parents may be unexpectedly billed for some hospitalization services, according to a research letter in JAMA Health Forum.
Novel antifungal treatment approved for vaginal candidiasis
On June 2, 2021, ibrexafungerp (Brexafemme; Scynexis, Inc) was approved by the Food and Drug Administration for vulvovaginal candidiasis (VVC) in adult women and pediatric females who have begun menstruating. Ibrexafungerp is a triterpenoid antifungal that works by inhibiting the formation of the fungal cell wall. Ibrexafungerp (pronounced eye-BREX-ah-FUN-jerp) is the first approved drug of a novel class of antifungals.
Visual Summary: Intrahepatic Cholestasis of Pregnancy
Refer to this visual summary from SMFM wherever you practice.
Meet the Board: Yalda Afshar, MD, PhD
Introducing Contemporary OB/GYN® Editorial Advisory Board member Yalda Afshar, MD, PhD.
Newsletter
Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.
Trimethoprim–sulfamethoxazole not found to increase infant birth weight in HIV cases
July 9th 2025A recent randomized trial found no significant improvement in birth weight or key birth outcomes from antenatal trimethoprim–sulfamethoxazole prophylaxis in human immunodeficiency virus-positive pregnant women.
Read More
